摘要
目的探讨RRM1与BRCA1在晚期非小细胞肺癌患者中的表达及与吉西他滨联合卡铂化疗预后的相关性。方法选取2014年1月至2015年1月间新疆医科大学第一附属医院收治的54例非小细胞肺癌患者,均采用吉西他滨联合卡铂化疗方案。化疗前检测肿瘤组织及外周血中BRCA1与RRM1的表达水平,分析肿瘤组织中的BRCA1和RRM1表达与吉西他滨联合卡铂化疗预后之间是否存在相关性。结果肿瘤组织中的RRM1和BRCA1含量均显著高于外周血;RRM1与BRCA1在肺癌组织中的表达间比较,差异无统计学意义(P>0.05)。患者中位总生存时间为15.6个月,其中1年生存率为61.1%,2年生存率为9.3%。RRM1低表达组患者的中位总生存时间为18.2个月,高表达组为13.7个月,差异有统计学意义(P<0.05)。BRCA1低表达组患者中位总生存时间为14.3个月,高表达组为13.9个月,差异无统计学意义(P>0.05)。结论肿瘤组织内的RRM1表达水平或可作为预测非小细胞肺癌患者吉西他滨联合卡铂治疗后预后的因子,对今后临床制订个体化的治疗方案具有重要的指导意义。
Objective To investigate the expression of RRM1 and BRCA1 and its correlation with prognosis of advanced non-small cell lung cancer（NSCLC） on combination chemotherapy of gemcitabine and carboplatin.Methods Fifty-four NSCLC patients treated at The First Affiliated Hospital of Xinjiang Medical University from January 2014 to January 2015 were selected.All patients received chemotherapy with gemcitabine plus carboplatin.The expression levels of BRCA1 and RRM1 in tumor tissues and peripheral blood were detected before chemotherapy,and the correlation between the expression of BRCA1 and RRM1 and the prognosis was analyzed.Results The expression levels of BRCA1 and RRM1 in tumor tissues were significantly higher than in the peripheral blood;there was no significant correlation between the expression of RRM1 and BRCA1 in lung cancer tissues（P0.05）.The follow-up survey showed that the median overall survival was 15.6 months,1-year survival rate was 61.1% and 2-year survival rate was 9.3%.The median overall survival was 18.2 months for patients with low expression of RRM1 and 13.7 months for patients with high expression of RRM1（P0.05）.The median overall survival was 14.3months for patients with low expression of BRCA1 and 13.9 months for patients with high expression of BRCA1（P0.05）.Conclusion The expression level of RRM1 in tumor tissue can be used as a predictive factor to determine the prognosis of NSCLC,which has an important guiding significance for the development of clinically individualized treatment plan in the future.
出处
《中国肿瘤临床与康复》
2017年第9期1028-1031,共4页
Chinese Journal of Clinical Oncology and Rehabilitation
基金
新疆维吾尔自治区自然科学基金(2014211C167)
关键词
癌
非小细胞肺
吉西他滨
卡铂
RRM1
BRCA1
Non-small cell lung cancer
Gemcitabine
Carboplatin
Clinical efficacy
RRM1
BRCA1
